Madrigal Pharmaceuticals, Inc.
MDGL
$531.78
-$8.11-1.50%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -3.04% | 11.77% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -3.04% | 11.77% | |||
| Cost of Revenue | 9.81% | 34.91% | |||
| Gross Profit | -4.09% | 10.21% | |||
| SG&A Expenses | 11.89% | 14.76% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 6.14% | -5.12% | |||
| Operating Income | -55.55% | 47.70% | |||
| Income Before Tax | -61.15% | 48.70% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -61.15% | 48.70% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -61.15% | 48.70% | |||
| EBIT | -55.55% | 47.70% | |||
| EBITDA | -55.93% | 47.88% | |||
| EPS Basic | -26.71% | 49.48% | |||
| Normalized Basic EPS | -26.71% | 48.22% | |||
| EPS Diluted | -26.71% | 49.48% | |||
| Normalized Diluted EPS | -26.71% | 48.22% | |||
| Average Basic Shares Outstanding | 27.17% | 1.54% | |||
| Average Diluted Shares Outstanding | 27.17% | 1.54% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||